Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Eton will expand its portfolio with ET-600 which is an innovative product candidate under development for the treatment of an endocrinology condition.
Lead Product(s): ET-600
Therapeutic Area: Endocrinology Product Name: ET-600
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Eton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 15, 2023